Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: a case report and literature review
Authors:
- Ryohei TakahashiRTRyohei Takahashi
- Kazunobu ShinodaKSKazunobu Shinoda
- Takashi IshidaTITakashi Ishida
- Yasuo HamamotoYHYasuo Hamamoto
- Shinya MoritaSMShinya Morita
- Hirotaka AkitaHAHirotaka Akita
- Sotaro KitaokaSKSotaro Kitaoka
- Satoshi TamakiSTSatoshi Tamaki
- Hiroshi AsanumaHAHiroshi Asanuma
- Tadashi YoshidaTYTadashi Yoshida
- Masahiro JinzakiMJMasahiro Jinzaki
- Kaori KameyamaKKKaori Kameyama
Open Access
- 3 April 2019
- journal article
- case report
- Published by Springer Nature in BMC Nephrology
- Vol. 20 (1) , 120
Abstract
Gastrointestinal stromal tumors (GISTs) in transplant recipients are very rare and only a handful of cases have been reported to date. Here we present the first known case of a huge GIST in a kidney transplant recipient with perforation of small intestine. A 64-year-old male presented at our hospital with right colic pain; he had received an ABO incompatible kidney transplant 6 years earlier and was treated with cyclosporine, mycophenolate mofetil, and methylprednisolone. Radiological evaluation revealed a huge (11 cm in diameter) solitary tumor at the small intestine without distant metastasis. The small intestinal wall at the tumor location was perforated one week after diagnosis and the patient underwent emergency surgery. The pathological findings were compatible with GIST and the tumor consisted of spindle cells with positive staining for KIT, CD34, and DOG1 and negative or weak staining for desmin and S-100 protein. A mutation in exon 11 of the c-kit gene was also detected. Cyclosporine was withdrawn and imatinib mesylate (400 mg daily) was introduced. However, thereafter, we needed to decrease the dose at 300 mg daily due to severe hyponatremia. Reduced imatinib treatment was well tolerated and recurrence was not observed for 18 months after surgery. The occurrence of GISTs in transplant patients is rare, and huge GISTs should be resected immediately after diagnosis because gastrointestinal tract at the tumor site could be perforated. Imatinib treatment is feasible in transplant recipients under immunosuppression, although immunosuppressive drugs metabolized by CYP3A4 should be used at a reduced dosage or withdrawn.Keywords
This publication has 21 references indexed in Scilit:
- Gastrointestinal stromal tumors in kidney transplant recipients: Report of two cases and literature reviewAsia-Pacific Journal of Clinical Oncology, 2016
- Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal TumorsCancer Research, 2013
- Metachronous Gastrointestinal Stromal Tumor and Acute Leukemia after Liver Transplantation for Cholangiocellular Carcinoma:Is There a LinkCase Reports in Oncology, 2013
- A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST PatientsClinical Cancer Research, 2012
- Extragastrointestinal Stromal Tumor and Liver Transplantation: Case Report and ReviewTransplantation Proceedings, 2008
- Gastrointestinal Stromal Tumor in a Liver Transplant RecipientTransplantation, 2008
- Gastrointestinal stromal tumours (GIST) in kidney transplant recipients--a report of two casesNephrology Dialysis Transplantation, 2007
- Clinical Pharmacokinetics of ImatinibClinical Pharmacokinetics, 2005
- Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.2003
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998